Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2R)-2-benzyl-3-nitropropanoic acid is a synthetic small molecule characterized by a propanoic acid backbone with a benzyl group at the 2-position and a nitro group at the 3-position. It acts as a potent inhibitor of carboxypeptidase A (CPA), an enzyme involved in proteolysis. The compound functions as a pseudo-transition-state analog inhibitor by mimicking the transition state of CPA-catalyzed hydrolysis; its nitro group coordinates to the zinc ion in CPA's active site and forms hydrogen bonds with key residues, resulting in strong inhibition (K(i) = 0.15 µM). This mechanism suggests potential utility as an experimental tool or lead compound for further drug development targeting metallocarboxypeptidases[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2R)-2-benzyl-3-nitropropanoic acid.